期刊文献+

胃癌HER-2表达与术后辅助化疗效果的相关性分析 被引量:2

Correlation Analysis between HER-2 Expression in Gastric Cancer and Curative Effect of Postoperative Adjuvant Chemotherapy
在线阅读 下载PDF
导出
摘要 目的:探讨胃癌HER-2阳性表达的临床病理特征及与胃癌术后辅助化疗效果的相关性。方法:选取2017年1月-2018年1月笔者所在医院47例胃癌切除术后行辅助化疗的患者,回顾性调研两组临床病理资料,比较观察两组无疾病进展生存时间(PFS)与总生存时间(OS),分析HER-2表达与临床指标的相关性。结果:47例患者中,HER-2阳性表达(试验组)24例,HER-2阴性表达(对照组)23例。两组性别、年龄、病变部位、TNM分期比较,差异无统计学意义(P>0.05),试验组Lauren分型肠型占比、肿瘤中分化占比和肿瘤直径5 cm以上病例占比均高于对照组,差异均有统计学意义(P<0.05)。试验组PFS与OS均短于对照组,差异均有统计学意义(P<0.05)。经Pearson相关性分析可知,HER-2表达与肿瘤大小呈正相关,与分型、分化及化疗后生存期呈负相关,差异均有统计学意义(P<0.05)。结论:胃癌HER-2表达与肿瘤大小、分型、分化、化疗后生存期等有关,阳性患者化疗后无疾病进展生存与总生存时间相对要短,获益效果不及阴性患者理想。 Objective:To investigate the correlation analysis between HER-2 expression in gastric cancer and curative effect of postoperative adjuvant chemotherapy.Method:From January 2017 to January 2018,47 patients who underwent adjuvant chemotherapy after gastric cancer resection in our hospital were selected.The clinical and pathological data of the two groups were retrospectively investigated,the disease progression-free survival time(PFS)and total survival time(OS)of the two groups were compared and observed,and the correlation between HER-2 expression and clinical indicators was analyzed.Result:Among the 47 patients,there were 24 patients with positive her-2 expression(experimental group)and 23 patients with negative HER-2 expression(control group).There were no statistically significant differences in gender,age,lesion site and TNM stage between the two groups(P>0.05).The proportion of Lauren type intestinal type,proportion of tumor differentiation in the experimental group,and proportion of cases with tumor diameter of more than 5 cm in the experimental group were all higher than those in the control group,the differences were statistically significant(P<0.05).The PFS and OS in the experimental group were shorter than those in the control group,the differences were statistically significant(P<0.05).Pearson correlation analysis showed that HER-2 expression was positively correlated with tumor size and negatively correlated with typing,differentiation and survival after chemotherapy,the differences were statistically significant(P<0.05).Conclusion:Gastric cancer HER-2 expression is related to tumor size,typing,differentiation,survival after chemotherapy.Positive patients have relatively short disease-free survival and overall survival after chemotherapy,and the benefit is less than that of negative patients.
作者 黄银梅 吴晓文 蔡东林 马宏武 HUANG Yinmei;WU Xiaowen;CAI Donglin;MA Hongwu(Chaoyang District Dafeng Hospital in Shantou City,Shantou 515154,China;不详)
出处 《中外医学研究》 2020年第21期156-158,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 胃癌 术后辅助化疗 HER-2表达 疗效 相关性 Gastric cancer Postoperative adjuvant chemotherapy HER-2 expression Curative effect Correlation
  • 相关文献

参考文献12

二级参考文献66

  • 1Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:345
  • 2Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 3Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278.
  • 4Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 5Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493.
  • 6Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ).
  • 7Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 8Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805.
  • 9Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217.
  • 10RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307.

共引文献185

同被引文献23

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部